Cipla Limited (CIPLA) — Board Meeting | 23 July 2025

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Cipla's board approved a final dividend of INR 15 per share and reappointed directors including Dr. K.A. Hamied and Mr. Umang Vohra, while appointing Walker Chandiok & Co LLP as statutory auditor. The meeting highlighted strong financials with INR 27,548 crores revenue, 27% net profit growth, and near-zero debt, alongside strategic capex plans of INR 2,200-2,500 crores annually for expansion in respiratory APIs and China facilities. Sustainability milestones included 67% renewable energy use and net water positivity, supporting long-term shareholder value through operational resilience and ESG alignment.

📄 View Original Announcement (PDF)

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day